Kalaris Therapeutics, Inc. (KLRS) Key Metrics
KLRS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $47.6M
- Enterprise value
- −$16.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.3
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
KLRS key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsKLRS valuation Price multiples at each fiscal year-end price.
KLRS returns How much profit the business earns on the capital it uses.
KLRS per-share figures Results divided by the shares outstanding at year-end.
KLRS financial health Debt, liquidity and how easily interest is covered.
KLRS efficiency & capital use Working capital cycle and where the cash goes.
KLRS valuation history
KLRS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
KLRS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
KLRS cash returned to shareholders
KLRS price vs earnings per share
KLRS key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $128.9M | $48.4M | — | — | — | — | — | — |
| Enterprise value | $12.3M | −$69.9M | — | — | — | — | — | — |
| Price / book | 1.6 | 0.4 | — | — | — | — | — | — |
| Earnings yield | −33.7% | −121.5% | — | — | — | — | — | — |
| Free cash flow yield | −33.5% | −139.9% | — | — | — | — | — | — |
| Share price at fiscal year-end | $8.44 | $9.66 | $15.64 | $117.99 | $297.62 | $884.12 | — | — |
| Per share | ||||||||
| Revenue per share | $0.00 | $0.00 | — | — | — | — | — | — |
| Earnings per share | −$2.85 | −$11.73 | — | — | — | — | — | — |
| Operating cash flow per share | −$2.81 | −$13.52 | — | — | — | — | — | — |
| Free cash flow per share | −$2.83 | −$13.52 | — | — | — | — | — | — |
| Cash per share | $7.73 | $23.62 | — | — | — | — | — | — |
| Book value per share | $5.16 | $22.62 | — | — | — | — | — | — |
| Tangible book value per share | $5.16 | $22.62 | — | — | — | — | — | — |
| Capex per share | $0.01 | $0.00 | — | — | — | — | — | — |
| Debt per share | $0.09 | — | — | — | — | — | — | — |
| Shares outstanding | 15.3M | 5.0M | — | — | — | — | — | — |
| Change in shares outstanding | +204.8% | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −45.2% | −172.1% | — | — | −59.5% | −29.4% | −33.3% | −11.3% |
| Return on invested capital (ROIC) | — | — | — | — | — | −884.5% | — | — |
| Return on assets (ROA) | −36.2% | −96.4% | −406.5% | −10.7% | −52.3% | −27.4% | −28.9% | −9.6% |
| Return on tangible assets | −35.7% | −49.6% | −441.0% | −397.2% | −60.0% | −18.8% | −17.1% | −9.6% |
| Free cash flow margin | — | — | — | — | — | — | — | 171.2% |
| Financial health | ||||||||
| Total debt | $1.4M | — | — | $3.3M | $30.1M | $8.7M | $11.8M | — |
| Cash & short-term investments | $118.0M | $118.3M | $3.2M | $3.1M | $248.1M | $356.3M | $126.1M | $25.0M |
| Net debt | −$116.5M | −$118.3M | −$3.2M | $194,000 | −$218.1M | −$347.6M | −$114.3M | −$25.0M |
| Debt / equity | 0.02 | — | — | — | 0.13 | 0.02 | 0.10 | — |
| Debt / assets | 0.01 | — | — | 0.83 | 0.10 | 0.02 | 0.08 | — |
| Current ratio | 12.23 | 22.63 | 0.85 | 0.69 | 6.69 | 29.39 | 13.98 | 6.77 |
| Quick ratio | 12.23 | 22.63 | 0.85 | 0.69 | 6.69 | 29.39 | 13.98 | 6.77 |
| Interest coverage | -32.0 | -20.5 | -19.6 | -59.6 | — | — | — | — |
| Working capital | $109.1M | $113.3M | −$609,000 | −$1.8M | $215.5M | $349.0M | $118.2M | $21.6M |
| Invested capital | −$37.7M | −$5.0M | −$48.2M | −$30.1M | $7.2M | $5.4M | $7.3M | −$3.4M |
| Tangible asset value | $78.8M | $113.3M | −$45.0M | −$30.3M | $225.3M | $353.1M | $121.6M | $21.6M |
| Net current asset value | $75.9M | $113.3M | −$45.0M | −$30.3M | $192.0M | $343.6M | $109.5M | $21.6M |
| Graham net-net per share | $4.92 | $22.57 | — | — | — | — | — | — |
| Capital allocation | ||||||||
| Share buybacks (net) | — | — | — | — | — | — | — | $10.0M |
| Dividends + buybacks / free cash flow | — | — | — | — | — | — | — | 514.7% |
| Capex / revenue | — | — | — | — | — | — | 205.5% | 0.0% |
| Capex / operating cash flow | — | — | — | — | — | — | — | 0.0% |
| Capex / depreciation | 15.38 | — | — | — | 0.02 | 3.22 | 17.84 | — |
| R&D / revenue | — | — | — | — | — | — | 9,835.8% | 149.8% |
| Efficiency | ||||||||
| Days sales outstanding | — | — | — | — | — | — | 953.4 | 97.1 |
| Days payables outstanding | 21,450.8 | — | — | — | 1,523.4 | 3,982.5 | — | — |
| Receivables turnover | — | — | — | — | 0.00 | 0.00 | 0.38 | 3.76 |
| Payables turnover | 0.02 | — | — | — | 0.24 | 0.09 | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 |
| Average receivables | — | — | — | — | $250,000 | $505,000 | $431,000 | $302,000 |
| Average payables | $764,000 | $1.3M | $2.6M | $5.6M | $4.7M | $796,500 | $391,500 | $153,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from KLRS's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
KLRS valuation and financial ratios
Kalaris Therapeutics earned a return on equity of −45.2% in fiscal 2025. It ended the year with $1.4 million of debt and $118.0 million in cash and short-term investments, a net cash position of $116.5 million.
See the KLRS income statement, the KLRS chart for price history, or the KLRS stock overview for the latest quote and news.
KLRS key metrics FAQ
What is Kalaris Therapeutics's return on equity?
Kalaris Therapeutics's return on equity (ROE) was −45.2% in fiscal 2025: net income of -$43.4 million on average shareholders' equity of $96.1 million.
How much debt does Kalaris Therapeutics have?
Kalaris Therapeutics had total debt of $1.4 million at the end of fiscal 2025, a debt-to-equity ratio of 0.02 and more cash than debt.
What is Kalaris Therapeutics's free cash flow yield?
Kalaris Therapeutics generated -$43.2 million of free cash flow in fiscal 2025, a free cash flow yield of −33.5% on its market value at year-end ($128.9 million).
What is Kalaris Therapeutics's current ratio?
Kalaris Therapeutics's current ratio was 12.23 at the end of fiscal 2025: current assets were 12.23 times current liabilities.